Krystal Biotech (KRYS) Tax Provisions (2023 - 2026)

Krystal Biotech has reported Tax Provisions for 4 years, with the latest figure at $11.3 million in Q2 2026.

• Tax Provisions for Q2 2026 came in at $11.3 million, up 33.98% year-over-year; the trailing twelve-month figure through Jun 2026 was -$14.8 million (down 167.33% YoY), and the FY2025 annual result was -$15.4 million, down 347.86% from the prior year.
• Tax Provisions climbed to $11.3 million in Q2 2026, from $5.5 million in the prior quarter.
• Over five years, Tax Provisions peaked at $11.3 million in Q2 2026 and troughed at -$31.4 million in Q3 2025.
• A 4-year average of $964200.0 and a median of $2.8 million in 2024 frame the typical range for Tax Provisions.
• The largest YoY upside for Tax Provisions was 1669.81% in 2025 against a maximum downside of 1307.69% in 2025.
• A 4-year view of Tax Provisions shows it stood at $2.0 million in 2023, then jumped by 57.61% to $3.1 million in 2024, then sank by 108.4% to -$260000.0 in 2025, then jumped by 4450.38% to $11.3 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $11.3 million in Q2 2026, $5.5 million in Q1 2026, and -$260000.0 in Q4 2025.